Invion Ltd Cash Flow Conversion Efficiency
Invion Ltd cash flow conversion efficiency. Based on the latest financial reports, Invion Ltd (IVX) has a cash flow conversion efficiency ratio of -0.163x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.34 Million ≈ $-951.19K USD) by net assets (AU$8.25 Million ≈ $5.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Invion Ltd (2006–2025)
Cash flow conversion efficiency of Invion Ltd from 2006 to 2025. This chart illustrates how Invion Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IVX live share price for real-time trading data and today's change.
Invion Ltd Cash Flow Conversion Ratio Explained
Invion Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Invion Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invion Ltd ranked by their cash flow conversion efficiency. Also see Invion Ltd stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smiths News PLC
LSE:SNWS
|
2.916x |
|
Chakana Copper Corp
V:PERU
|
-0.248x |
|
Trxade Group Inc
NASDAQ:MEDS
|
0.358x |
|
Shuttle Pharmaceuticals Inc
NASDAQ:SHPH
|
-0.722x |
|
Frontier Developments Plc
LSE:FDEV
|
0.241x |
|
Goldhills Holding Ltd
V:GHL
|
0.014x |
|
ELEMENT NUTR.SCIENCES
F:93X
|
0.014x |
|
Aker Carbon Capture ASA
OL:ACC
|
-0.772x |
Annual Cash Flow Conversion Efficiency for Invion Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Invion Ltd from 2006 to 2025. Review IVX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$8.25 Million ≈ $5.84 Million |
AU$-2.97 Million ≈ $-2.10 Million |
-0.360x | -116.34% |
| 2024-06-30 | AU$14.44 Million ≈ $10.22 Million |
AU$-2.40 Million ≈ $-1.70 Million |
-0.166x | -68.80% |
| 2023-06-30 | AU$18.40 Million ≈ $13.02 Million |
AU$-1.81 Million ≈ $-1.28 Million |
-0.099x | -73.98% |
| 2022-06-30 | AU$19.58 Million ≈ $13.85 Million |
AU$-1.11 Million ≈ $-784.62K |
-0.057x | -164.92% |
| 2021-06-30 | AU$4.79 Million ≈ $3.39 Million |
AU$417.98K ≈ $295.74K |
0.087x | +410.95% |
| 2020-06-30 | AU$5.43 Million ≈ $3.84 Million |
AU$-152.47K ≈ $-107.88K |
-0.028x | +92.73% |
| 2019-06-30 | AU$5.46 Million ≈ $3.86 Million |
AU$-2.11 Million ≈ $-1.49 Million |
-0.386x | -531.44% |
| 2018-06-30 | AU$7.91 Million ≈ $5.59 Million |
AU$707.09K ≈ $500.31K |
0.089x | +245.01% |
| 2017-06-30 | AU$4.01 Million ≈ $2.84 Million |
AU$-247.14K ≈ $-174.87K |
-0.062x | +90.36% |
| 2016-06-30 | AU$5.99 Million ≈ $4.24 Million |
AU$-3.83 Million ≈ $-2.71 Million |
-0.640x | +56.67% |
| 2015-06-30 | AU$6.86 Million ≈ $4.85 Million |
AU$-10.13 Million ≈ $-7.17 Million |
-1.477x | -244.59% |
| 2014-06-30 | AU$10.16 Million ≈ $7.19 Million |
AU$-4.35 Million ≈ $-3.08 Million |
-0.429x | -36.75% |
| 2013-06-30 | AU$11.04 Million ≈ $7.81 Million |
AU$-3.46 Million ≈ $-2.45 Million |
-0.313x | +82.26% |
| 2012-06-30 | AU$6.01 Million ≈ $4.25 Million |
AU$-10.62 Million ≈ $-7.51 Million |
-1.766x | -128.12% |
| 2011-06-30 | AU$-2.14 Million ≈ $-1.52 Million |
AU$-13.46 Million ≈ $-9.52 Million |
6.281x | +97.36% |
| 2010-06-30 | AU$-4.78 Million ≈ $-3.38 Million |
AU$-15.20 Million ≈ $-10.76 Million |
3.182x | +4.10% |
| 2008-06-30 | AU$-3.23 Million ≈ $-2.28 Million |
AU$-9.86 Million ≈ $-6.98 Million |
3.057x | +117.84% |
| 2007-06-30 | AU$715.28K ≈ $506.11K |
AU$-12.26 Million ≈ $-8.67 Million |
-17.134x | -597.95% |
| 2006-06-30 | AU$4.83 Million ≈ $3.42 Million |
AU$-11.87 Million ≈ $-8.40 Million |
-2.455x | -- |
About Invion Ltd
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also in… Read more